1. volunteer involvement in another study over the last 90 days; 2. any vaccination over the last 30 days; 3. history of covid-2019 disease; 4. positive pcr test results for sars-cov-2 (during the screening); 5. positive test results for igm and igg antibodies to sars-cov-2; 6. health staff in contact with people with covid-2019; 7. respiratory symptoms in the last 14 days; 8. the administration of immunoglobulins or other blood products in the last 3 months; 9. regular current or past use of narcotic drugs; 10. subject has received immunosuppressive and/or immunomodulating agents within 6 months before the start of the study; 11. pregnancy or breast feeding; 12. exacerbation of allergic diseases at the time of vaccination; 13. subject has systolic blood pressure less than 100 mm hg or greater than 139 mm hg; diastolic blood pressure less than 60 mm hg or greater than 90 mm hg; heart rate lower than 60 beats per minute or above 100 beats per minute; 14. a burdened allergic history (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, a history of serum sickness, hypersensitivity or allergic reactions to the introduction of any vaccines in history, known allergic reactions to vaccine components, etc.); 15. a history of autoimmune diseases in the volunteer's medical history and in relatives' medical history of the 1-2 degree of kinship; 16. subject smokes more than 10 cigarettes per day; 17. alcohol intake exceeding the low-risk level: no more than 20 grams of pure alcohol per day, no more than 5 days a week, alcohol intake within 48 hours before the administration of the drug; 18. planned hospitalization and/or surgery during the period of participation in the study, as well as 4 weeks before the expected date of the administration of the drug; 19. the presence of an associated disease that may affect the assessment of the results of the study; 20. any conditions that, according to the researcher's doctor, may be a contraindication to the participation in the study.

1. volunteer involvement in another study over the last 90 days; 2. any vaccination over the last 30 days; 3. history of covid-2019 disease; 4. positive pcr test results for sars-cov-2 (during the screening); 5. positive test results for igm and igg antibodies to sars-cov-2; 6. health staff in contact with people with covid-2019; 7. respiratory symptoms in the last 14 days; 8. the administration of immunoglobulins or other blood products in the last 3 months; 9. regular current or past use of narcotic drugs; 10. subject has received immunosuppressive and/or immunomodulating agents within 6 months before the start of the study; 11. pregnancy or breast feeding; 12. exacerbation of allergic diseases at the time of vaccination; 13. subject has systolic blood pressure less than 100 mm hg or greater than 139 mm hg; diastolic blood pressure less than 60 mm hg or greater than 90 mm hg; heart rate lower than 60 beats per minute or above 100 beats per minute; 14. a burdened allergic history (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, a history of serum sickness, hypersensitivity or allergic reactions to the introduction of any vaccines in history, known allergic reactions to vaccine components, etc.); 15. a history of autoimmune diseases in the volunteer's medical history and in relatives' medical history of the 1-2 degree of kinship; 16. subject smokes more than 10 cigarettes per day; 17. alcohol intake exceeding the low-risk level: no more than 20 grams of pure alcohol per day, no more than 5 days a week, alcohol intake within 48 hours before the administration of the drug; 18. planned hospitalization and/or surgery during the period of participation in the study, as well as 4 weeks before the expected date of the administration of the drug; 19. the presence of an associated disease that may affect the assessment of the results of the study; 20. any conditions that, according to the researcher's doctor, may be a contraindication to the participation in the study.

volunteer involvement in another study over the last 90 days; any vaccination over the last 30 days; history of covid-2019 disease; positive pcr test results for sars-cov-2 (during the screening); positive test results for igm and igg antibodies to sars-cov-2; health staff in contact with people with covid-2019; respiratory symptoms in the last 14 days; the administration of immunoglobulins or other blood products in the last 3 months; regular current or past use of narcotic drugs; subject has received immunosuppressive and/or immunomodulating agents within 6 months before the start of the study; pregnancy or breast feeding; exacerbation of allergic diseases at the time of vaccination; subject has systolic blood pressure less than 100 mm hg or greater than 139 mm hg; diastolic blood pressure less than 60 mm hg or greater than 90 mm hg; heart rate lower than 60 beats per minute or above 100 beats per minute; a burdened allergic history (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, a history of serum sickness, hypersensitivity or allergic reactions to the introduction of any vaccines in history, known allergic reactions to vaccine components, etc.); a history of autoimmune diseases in the volunteer's medical history and in relatives' medical history of the 1-2 degree of kinship; subject smokes more than 10 cigarettes per day; alcohol intake exceeding the low-risk level: no more than 20 grams of pure alcohol per day, no more than 5 days a week, alcohol intake within 48 hours before the administration of the drug; planned hospitalization and/or surgery during the period of participation in the study, as well as 4 weeks before the expected date of the administration of the drug; the presence of an associated disease that may affect the assessment of the results of the study; any conditions that, according to the researcher's doctor, may be a contraindication to the participation in the study.

volunteer involvement in another study over the last 90 days; any vaccination over the last 30 days; history of covid-2019 disease; positive pcr test results for sars-cov-2 (during the screening); positive test results for igm and igg antibodies to sars-cov-2; health staff in contact with people with covid-2019; respiratory symptoms in the last 14 days; the administration of immunoglobulins or other blood products in the last 3 months; regular current or past use of narcotic drugs; subject has received immunosuppressive and/or immunomodulating agents within 6 months before the start of the study; pregnancy or breast feeding; exacerbation of allergic diseases at the time of vaccination; subject has systolic blood pressure less than 100 mm hg or greater than 139 mm hg; diastolic blood pressure less than 60 mm hg or greater than 90 mm hg; heart rate lower than 60 beats per minute or above 100 beats per minute; a burdened allergic history (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, a history of serum sickness, hypersensitivity or allergic reactions to the introduction of any vaccines in history, known allergic reactions to vaccine components, etc.); a history of autoimmune diseases in the volunteer's medical history and in relatives' medical history of the 1-2 degree of kinship; subject smokes more than 10 cigarettes per day; alcohol intake exceeding the low-risk level: no more than 20 grams of pure alcohol per day, no more than 5 days a week, alcohol intake within 48 hours before the administration of the drug; planned hospitalization and/or surgery during the period of participation in the study, as well as 4 weeks before the expected date of the administration of the drug; the presence of an associated disease that may affect the assessment of the results of the study; any conditions that, according to the researcher's doctor, may be a contraindication to the participation in the study.

1. volunteer involvement in another study over the last 90 days; 2. any vaccination over the last 30 days; 3. history of covid-2019 disease; 4. positive pcr test results for sars-cov-2 (during the screening); 5. positive test results for igm and igg antibodies to sars-cov-2; 6. health staff in contact with people with covid-2019; 7. respiratory symptoms in the last 14 days; 8. the administration of immunoglobulins or other blood products in the last 3 months; 9. regular current or past use of narcotic drugs; 10. subject has received immunosuppressive and/or immunomodulating agents within 6 months before the start of the study; 11. pregnancy or breast feeding; 12. exacerbation of allergic diseases at the time of vaccination; 13. subject has systolic blood pressure less than 100 mm hg or greater than 139 mm hg; diastolic blood pressure less than 60 mm hg or greater than 90 mm hg; heart rate lower than 60 beats per minute or above 100 beats per minute; 14. a burdened allergic history (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, a history of serum sickness, hypersensitivity or allergic reactions to the introduction of any vaccines in history, known allergic reactions to vaccine components, etc.); 15. a history of autoimmune diseases in the volunteer's medical history and in relatives' medical history of the 1-2 degree of kinship; 16. subject smokes more than 10 cigarettes per day; 17. alcohol intake exceeding the low-risk level: no more than 20 grams of pure alcohol per day, no more than 5 days a week, alcohol intake within 48 hours before the administration of the drug; 18. planned hospitalization and/or surgery during the period of participation in the study, as well as 4 weeks before the expected date of the administration of the drug; 19. the presence of an associated disease that may affect the assessment of the results of the study; 20. any conditions that, according to the researcher's doctor, may be a contraindication to the participation in the study.

1. volunteer involvement in another study over the last 90 days; 2. any vaccination over the last 30 days; 3. history of covid-2019 disease; 4. positive pcr test results for sars-cov-2 (during the screening); 5. positive test results for igm and igg antibodies to sars-cov-2; 6. health staff in contact with people with covid-2019; 7. respiratory symptoms in the last 14 days; 8. the administration of immunoglobulins or other blood products in the last 3 months; 9. regular current or past use of narcotic drugs; 10. subject has received immunosuppressive and/or immunomodulating agents within 6 months before the start of the study; 11. pregnancy or breast feeding; 12. exacerbation of allergic diseases at the time of vaccination; 13. subject has systolic blood pressure less than 100 mm hg or greater than 139 mm hg; diastolic blood pressure less than 60 mm hg or greater than 90 mm hg; heart rate lower than 60 beats per minute or above 100 beats per minute; 14. a burdened allergic history (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, a history of serum sickness, hypersensitivity or allergic reactions to the introduction of any vaccines in history, known allergic reactions to vaccine components, etc.); 15. a history of autoimmune diseases in the volunteer's medical history and in relatives' medical history of the 1-2 degree of kinship; 16. subject smokes more than 10 cigarettes per day; 17. alcohol intake exceeding the low-risk level: no more than 20 grams of pure alcohol per day, no more than 5 days a week, alcohol intake within 48 hours before the administration of the drug; 18. planned hospitalization and/or surgery during the period of participation in the study, as well as 4 weeks before the expected date of the administration of the drug; 19. the presence of an associated disease that may affect the assessment of the results of the study; 20. any conditions that, according to the researcher's doctor, may be a contraindication to the participation in the study.